Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk - Wikidata - awgldk - TriplyDB

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk

http://www.wikidata.org/entity/Q28076223

about

Treatment with triple combination of atorvastatin, perindopril, and amlodipine in patients with stable coronary artery disease: A subgroup analysis from the PAPA-CAD study.

P2860

Q52647190-487C8C71-48B9-45B0-8F59-036A135B60EB

P2860

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk

http://www.wikidata.org/entity/Q28076223

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@ast

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@en

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@nl

type

label

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@ast

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@en

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@nl

prefLabel

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@ast

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@en

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@nl

P1433

Q28076223-80A90A02-D92B-4FD9-9273-D37A37DCD7D1

P1476

Q28076223-AF8C89C7-F0C7-41EB-9B82-C83B3703EFC4

P2093

Q28076223-9C51DDA6-E74E-431B-8E9F-32B57DA8AB25

Q28076223-B6BADC06-6C95-4E99-87C6-6BDD62F8D9F6

P275

Q28076223-3ED2050D-8DC7-4166-A948-DB0162675AB8

P2860

Q28076223-1045AF7E-26BB-448A-B39D-F82C3A09848B

Q28076223-12E6440C-20B1-4D51-879E-DCD2D22AC1E2

Q28076223-15939212-953E-4169-A350-6A52E6110F3E

Q28076223-15D3ADF5-733A-483E-88F4-27CEC3588FDB

Q28076223-1DA3210E-A1A9-403E-A2A0-819AC66C7C2F

Q28076223-2BAD8264-9EA6-495D-9433-B75D23ED0126

Q28076223-2C6272E1-B43F-4097-9475-057701DA699F

Q28076223-324C99C9-D097-4976-AFE5-5B3A4489DD25

Q28076223-34703FC0-1082-4E97-BB02-FDC853A8DC6B

Q28076223-47A76188-B01E-4844-866D-7AB4E08FDDE7

P2888

Q28076223-67FB4B83-3B62-474D-BC02-0932E5E035D5

P304

Q28076223-7BDAD0CF-CC7F-4FC9-9EFB-5F62C08BD44E

P31

Q28076223-23AE55C4-95ED-4FF2-BB3A-3FD85E999293

Q28076223-4E4B49CC-5124-411E-B483-E889635AFBD7

P3181

Q28076223-FAA4EBD4-D5DA-413C-9E64-8EF66D0C88B2

P356

Q28076223-D9DF9077-50D4-4B28-81FA-39B6A4FF9E04

P407

Q28076223-8D91126E-D9E3-4015-8838-A87F0F638492

P433

Q28076223-5DE76635-8405-4C1A-B7AF-091522113F7D

P478

Q28076223-93A76D0E-DC9C-41C2-A49B-797D6EEADBE0

P5008

Q28076223-8184976F-D968-45FC-BF50-82CA9CB905EB

P577

Q28076223-2C6C1293-7942-44B4-802B-F68E79AED4E8

Q28076223-4E457811-45B3-47AE-8E91-B901EB1A3532

P6179

Q28076223-77A77139-9E86-4451-BF33-407217096644

P698

Q28076223-48599B5A-16C2-46B9-A4ED-246E1F60A5FF

P921

Q28076223-6ADAA9CD-5377-4C4E-8F00-753ED5461EB0

Q28076223-B89531C6-CD7D-492D-BC80-A24B61957765

Q28076223-F4C2FD47-23AA-47CB-8E9D-CB7765DB4DD6

P932

Q28076223-63F6052B-15FC-42E4-8766-30AF73F202B3

P3181

P356

S40256-016-0185-0

P1433

American journal of cardiovascular drugs

P1476

Effects of Angiotensin-Convert ...... and Myocardial Infarction Risk

@en

P2093

Csaba András Dézsi

http://www.w3.org/2001/XMLSchema#string

Veronika Szentes

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Telmisartan, ramipril, or both in patients at high risk for vascular events.

The complex puzzle underlying the pathophysiology of acute coronary syndromes: from molecular basis to clinical manifestations.

Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

P2888

s40256-016-0185-0

P304

399-406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3796242

http://www.w3.org/2001/XMLSchema#string

P356

10.1007/S40256-016-0185-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009941977

http://www.w3.org/2001/XMLSchema#string

P698

27580998

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

P932

5126203

http://www.w3.org/2001/XMLSchema#string